- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
A New Biomarker Predicts Response to Pembrolizumab in Advanced Melanoma
A new study by researchers at the Perelman School of Medicine at the University of Pennsylvania has identified a biomarker that can predict response to treatment with pembrolizumab in stage IV patients with melanoma.
Predictive biomarkers—those that can ascertain the success of a treatment—can be very useful in deciding early on if a patient should continue on a treatment plan. Now, a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania has identified such a biomarker in stage IV patients with melanoma being treated with the immunotherapy pembrolizumab (Keytruda).
In their study presented at the CRICIMT- EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, the authors found that the ratio of a subset of immune cells in the blood to the tumor burden correlated with clinical response. “We set out to investigate whether we could monitor and predict a patient’s response to pembrolizumab by tracking the effect of pembrolizumab on immune cells in blood samples from the patients,” said lead author Alexander Huang, MD, clinical fellow in the Division of Hematology/ Oncology and Institute for Immunology at Perelman.
The researchers monitored 29 patients with advanced stage IV melanoma by analyzing immune cells in their blood that was collected before and at 3, 6, 9, and 12 weeks after initiating treatment with pembrolizumab. The authors were primarily interested in following the proliferation of exhausted phenotype CD8+ T cells, which have high levels of programmed death ligand-1 (PD-L1) on their cell surface. These cells are so named because they are no longer capable of inhibiting tumor cells. Pembrolizumab can reinvigorate exhausted phenotype CD8+ T cells, which can be measured by their proliferative capacity.
The authors identified increased proliferation of exhausted phenotype CD8+ T cells in 78% of patients, post treatment. When they calculated the ratio of exhausted phenotype CD8+ T cell reinvigoration to pretreatment tumor burden, a correlation with clinical response was noted. Using this calculation, a clinical response was observed in 38% patients. In one cohort, half the patients with a clinical response exceeding 1.94 were alive at 11-months post treatment with pembrolizumab. In another cohort, 75% of patients with a ratio greater than 1.94 were alive a 2-years post treatment. “We were excited to find that patients with a balance in favor of the immune response compared to tumor burden were more likely to have clinical benefit,” Huang said, adding that their findings need validation in a larger study.Reference
Ratio of certain immune cells to tumor burden correlated with outcome for pembrolizumab-treated patients with melanoma [press release]. New York, NY: American Association for Cancer Research; September 26, 2016. http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=939#.V-qy9_krLIX. Accessed September 26, 2016.
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
February 20th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The February issue features a retrospective by Richard J. Gilfillan, MD, former director of the Center for Medicare and Medicaid Innovation; and Donald M. Berwick, MD, MPP, former administrator of CMS.
Read More
Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans
February 10th 2025This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
Read More
